| 5.915 0.175 (3.05%) | 11-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.8 | 1-year : | 9.01 |
| Resists | First : | 6.68 | Second : | 7.71 |
| Pivot price | 6.59  |
|||
| Supports | First : | 5.01 | Second : | 4.16 |
| MAs | MA(5) : | 6 |
MA(20) : | 6.7 |
| MA(100) : | 8.96 |
MA(250) : | 11.36 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 33.7 |
D(3) : | 38.5 |
| RSI | RSI(14): 34.8  |
|||
| 52-week | High : | 18.3 | Low : | 5.01 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PHAT ] has closed above bottom band by 18.9%. Bollinger Bands are 13.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.33 - 6.36 | 6.36 - 6.39 |
| Low: | 5.52 - 5.56 | 5.56 - 5.6 |
| Close: | 5.68 - 5.74 | 5.74 - 5.79 |
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Fri, 30 Oct 2026
Phathom Pharmaceuticals, Inc. (PHAT) Seasonal returns chart - Yahoo Finance Australia
Thu, 29 Oct 2026
Phathom Pharmaceuticals Inc (PHAT) (Q3 2026) Earnings Call Highlights: Second Consecutive ... - Yahoo Finance
Thu, 29 Oct 2026
What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call - Yahoo Finance
Thu, 29 Oct 2026
Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates - Yahoo Finance
Thu, 29 Oct 2026
Phathom Pharmaceuticals Inc (PHAT) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Mon, 26 Oct 2026
Phathom Pharmaceuticals Provides Update on FDA Litigation - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 81 (M) |
| Shares Float | 65 (M) |
| Held by Insiders | 4.6 (%) |
| Held by Institutions | 94.3 (%) |
| Shares Short | 10,110 (K) |
| Shares Short P.Month | 10,820 (K) |
| EPS | -1.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -4.31 |
| Profit Margin | -41.4 % |
| Operating Margin | -5.4 % |
| Return on Assets (ttm) | -8.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 88 % |
| Gross Profit (p.s.) | 2.45 |
| Sales Per Share | 2.96 |
| EBITDA (p.s.) | -0.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -37 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -4.62 |
| PEG Ratio | 0 |
| Price to Book value | -1.36 |
| Price to Sales | 1.96 |
| Price to Cash Flow | -12.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|